About Us

Illexcor Therapeutics was founded in 2020 based on a collaboration between Virginia Commonwealth University, Children’s Hospital of Philadelphia, and King Abdulaziz University. Each of these esteemed Universities have a long history of drug discovery for sickle cell disease. Our founding scientists have been searching for small molecule drugs for sickle cell disease since the 1990s. Illexcor Therapeutics is a culmination of their development efforts over the decades.

The key focus of Illexcor Therapeutics is on executing a development program for our lead drug ILX002 for the treatment of sickle cell disease. This program has been been sponsored in part by the National Heart, Lung, and Blood Institute.